Research map: From Genetic Testing to Prevention: An Integrated Clinical Pathway for Hereditary Risk Assessment in Tubo-Ovarian Cancer

Back to the article

Papers in this map

  1. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology · Sue M. Richards · 2015 · 33500 citations · Cited by this paper
  2. Beyond p53 status: the continued importance of histopathologic features for predicting lymph node metastasis in endometrial cancer · 2026 · Related
  3. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers · Karoline B. Kuchenbaecker · 2017 · 3030 citations · Cited by this paper
  4. Integration of Immuno-Nutritional Status into International Federation of Gynecology and Obstetrics Risk Stratification to Predict Chemotherapy Response and Survival in Gestational Trophoblastic Neoplasia · 2026 · Related
  5. Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers · Timothy R. Rebbeck · 2009 · 949 citations · Cited by this paper
  6. From intensification to selection: the next challenge in advanced or recurrent endometrial cancer · 2026 · Related
  7. Inherited Mutations in Women With Ovarian Carcinoma · Barbara M. Norquist · 2015 · 781 citations · Cited by this paper
  8. Pre-operative Nutritional Risk Screening 2002-based nomograms for predicting post-operative complications after cytoreductive surgery for ovarian cancer: a multi-center retrospective cohort study · 2026 · Related
  9. BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors · Andrew Lee · 2019 · 770 citations · Cited by this paper
  10. Giant vulvar plexiform neurofibroma in neurofibromatosis type 1 · 2026 · Related
  11. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial · Usha Menon · 2021 · 738 citations · Cited by this paper
  12. Efficacy and safety of immune checkpoint inhibitor rechallenge in cervical and endometrial cancer: a multi-center retrospective study (RICE study) · 2026 · Related
  13. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database · Mev Dominguez–Valentin · 2019 · 682 citations · Cited by this paper
  14. Cadonilimab for recurrent small cell neuroendocrine carcinoma of the cervix: a phase 2 study · 2026 · Related
  15. Impact of Oophorectomy on Cancer Incidence and Mortality in Women With a BRCA1 or BRCA2 Mutation · Amy Finch · 2014 · 672 citations · Cited by this paper
  16. DICER1-Associated Gynecologic Neoplasms: An Update and Review · 2025 · Related
  17. Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type · Leora Witkowski · 2014 · 515 citations · Cited by this paper
  18. Consent model for tumour genetic testing in ovarian cancer · 2025 · Related
  19. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer · Rowan E. Miller · 2020 · 504 citations · Cited by this paper
  20. Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer · Susan J. Ramus · 2015 · 447 citations · Cited by this paper
  21. Cancer Risks Associated With GermlinePALB2Pathogenic Variants: An International Study of 524 Families · Xin Yang · 2019 · 440 citations · Cited by this paper
  22. Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4 · Pilar Ramos · 2014 · 396 citations · Cited by this paper
  23. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline · Panagiotis A. Konstantinopoulos · 2020 · 388 citations · Cited by this paper
  24. Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers · Karoline B. Kuchenbaecker · 2016 · 360 citations · Cited by this paper
  25. ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease · Jonathan A. Ledermann · 2024 · 328 citations · Cited by this paper
  26. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions · Johnathan M. Lancaster · 2014 · 303 citations · Cited by this paper
  27. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline · Cristiana Sessa · 2022 · 303 citations · Cited by this paper
  28. Prevalence of Variant Reclassification Following Hereditary Cancer Genetic Testing · Jacqueline A Mersch · 2018 · 274 citations · Cited by this paper
  29. CanRisk Tool—A Web Interface for the Prediction of Breast and Ovarian Cancer Risk and the Likelihood of Carrying Genetic Pathogenic Variants · Tim Carver · 2021 · 242 citations · Cited by this paper
  30. Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients · Angela Joy George · 2016 · 232 citations · Cited by this paper
  31. Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D · Xin Yang · 2020 · 176 citations · Cited by this paper
  32. Cascade Testing for Hereditary Cancer Syndromes: Should We Move Toward Direct Relative Contact? A Systematic Review and Meta-Analysis · Melissa Kristen Frey · 2022 · 155 citations · Cited by this paper
  33. EPCAM deletion carriers constitute a unique subgroup of Lynch syndrome patients · Marjolijn J. L. Ligtenberg · 2012 · 148 citations · Cited by this paper
  34. Clinical significance of large rearrangements in BRCA1 and BRCA2 · Thaddeus Judkins · 2012 · 136 citations · Cited by this paper
  35. Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline · Nadine Tung · 2024 · 114 citations · Cited by this paper
  36. Specifying the ovarian cancer risk threshold of ‘premenopausal risk-reducing salpingo-oophorectomy’ for ovarian cancer prevention: a cost-effectiveness analysis · Ranjit Manchanda · 2016 · 83 citations · Cited by this paper
  37. Hereditary Cancer Syndromes and Risk Assessment · 2019 · 83 citations · Cited by this paper
  38. Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes — Providing evidence of cancer predisposition genes · Malwina Suszyńska · 2019 · 80 citations · Cited by this paper
  39. Management of individuals with germline variants in PALB2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG) · Marc D. Tischkowitz · 2021 · 77 citations · Cited by this paper

Source: OpenAlex (CC0)